November 07, 2018: Achillion Reports Third Quarter 2018 Financial Results
September 25, 2018: Achillion to Present at the Leerink Partners Roundtable Series
September 10, 2018: Achillion Appoints Paul Firuta Chief Operating Officer
Module 1 "What is the complement system?"
Module 2 "What is the Alternative Pathway?"
Module 5 "Achillion Pharmaceuticals"
Modules 1-5: FACTOR D - A Trigger Point for Complement Activity by Achillion Pharmaceuticals
Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, provided the opening remarks at the first Complement Symposium, hosted by Achillion, which was held in Orlando, Florida during the American Society of Hematology 2015 Annual Meeting,December 6, 2015.
Dr. Peter Densen, M.D., Professor of Internal Medicine – Infectious Disease, University of Iowa, provided a detailed look at the role of thecomplement system and the relative risks of infection associated with immune modulation.
Dr. Scott Barnum, Ph.D., Department of Microbiology at the University of Alabama at Birmingham, presented a review of complement immune-biology and the roles of the classical, lectin, and alternative pathways.
Dr. David Apelian, M.D., Ph.D., Chief Medical Officer of Achillion Pharmaceuticals, discussing the nomination of ACH-4471, small-molecule complement factor D inhibitor, being developed for the treatment of ultra-rare diseases, including PNH.
Achillion discovered and developed a portfolio of antivirals for the treatment of HCV. In May 2015, the company entered into a worldwide license and collaboration agreement with Janssen Pharmaceuticals to their optimize clinical development and commercialization.
Achillion is headquartered in New Haven, CT, and is part of the vibrant bioscience R&D community in the city.
Achillion currently has more than 80 employees, 70% of which have an advanced degree in their field.
Our company logo depicts Achilles, the Greek hero of the Trojan War and the central character in Homer’s The Illiad.
Achillion was founded in 1998 when a group of researchers formed a company that would pursue potential new treatments for infectious disease.
Our company has generated high-resolution 3D structures of factor D inhibitor complexes, which has advanced our work in developing small molecule factor D inhibitors.